BidaskClub upgraded shares of DBV Technologies S.A. (NASDAQ:DBVT) from a hold rating to a buy rating in a research report released on Tuesday.

A number of other research analysts have also issued reports on DBVT. Zacks Investment Research upgraded shares of DBV Technologies from a sell rating to a hold rating in a report on Friday, March 31st. Jefferies Group LLC restated a buy rating and issued a $47.00 target price on shares of DBV Technologies in a report on Thursday, June 1st. Deutsche Bank AG started coverage on shares of DBV Technologies in a report on Friday, June 23rd. They issued a buy rating and a $46.00 target price on the stock. ValuEngine raised shares of DBV Technologies from a sell rating to a hold rating in a research note on Saturday, June 24th. Finally, HC Wainwright reaffirmed a buy rating and set a $50.00 price objective on shares of DBV Technologies in a research note on Thursday, July 6th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $47.00.

DBV Technologies (DBVT) traded up 1.15% during midday trading on Tuesday, reaching $43.82. 67,273 shares of the company traded hands. The firm’s market capitalization is $2.02 billion. DBV Technologies has a 12 month low of $31.87 and a 12 month high of $44.95. The company’s 50-day moving average price is $37.81 and its 200 day moving average price is $35.45.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.watchlistnews.com/dbv-technologies-s-a-nasdaqdbvt-upgraded-by-bidaskclub-to-buy/1461547.html.

Several hedge funds and other institutional investors have recently bought and sold shares of DBVT. Alliancebernstein L.P. increased its position in DBV Technologies by 21.1% in the first quarter. Alliancebernstein L.P. now owns 996,535 shares of the company’s stock worth $35,098,000 after buying an additional 173,798 shares in the last quarter. Morgan Stanley increased its position in DBV Technologies by 89.9% in the first quarter. Morgan Stanley now owns 249,988 shares of the company’s stock worth $8,805,000 after buying an additional 118,317 shares in the last quarter. Marshall Wace North America L.P. bought a new position in DBV Technologies during the first quarter worth approximately $3,566,000. MARSHALL WACE ASIA Ltd bought a new position in DBV Technologies during the first quarter worth approximately $3,566,000. Finally, Norges Bank bought a new position in DBV Technologies during the fourth quarter worth approximately $1,757,000. 48.20% of the stock is owned by institutional investors.

About DBV Technologies

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Analyst Recommendations for DBV Technologies (NASDAQ:DBVT)

Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with Analyst Ratings Network's FREE daily email newsletter.